associated antigens more than 30 y ago and the development of hybridoma technology in 1975, investigators realized that Paul Ehrlich's vision to effectively target drugs to diseased tissues could be tested. It was shown that monoclonal antibodies could specifically target tumors (1, 2) , and it was hypothesized that cancer could be treated with naked antibodies by inducing antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, or apoptosis or with antibodies tagged with cytotoxic drugs or radionuclides. Indeed, in the early
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1980s, clinical studies provided the proof of principle that tumors could be visualized using radiolabeled antibodies. As a result, a few labeled antibody products were marketed for scintigraphic imaging of tumors: satumomab pendetide (OncoScint; Cytogen Corp.) for colorectal and ovarian carcinoma, arcitumomab (CEA scan) for colorectal cancers, nofetumomab merpetan (Verluma; BoehringerIngelheim Pharma KG) for small cell lung carcinoma, and capromab pentetide (ProstaScint; EUSA Pharma) for prostate cancer. However, the diagnostic accuracy of these antibody-based scans was limited, and when 18 F-FDG PET was introduced in the clinic, antibodybased imaging for staging and restaging of cancer patients became obsolete. In most groups of cancer patients, the sensitivity and specificity of 18 F-FDG PET was superior and the resolution of the images was higher. Moreover, quantitative analysis of the images provided valuable information about tumor metabolism and response to therapy.
In Carrasquillo et al. reported that 9 of 12 primary tumors and most liver metastases in these patients were visualized with 124 I-labeled huA33, with a median tumor-to-background ratio of 4:1 (3), which is comparable to the results of previous imaging studies when the same antibody was labeled with 131 I (4,5). Obviously, the resolution of the 124 I images is better than the resolution of the 131 I images, but this improvement will only marginally improve the diagnostic accuracy of the images, as accuracy is determined mainly by the target-tobackground ratios. On the other hand, immuno-PET of cancer can be clinically relevant by adding specificity when undetermined masses are evaluated, as has been shown by the same group of investigators in patients suspected of renal cell carcinoma who were scheduled to undergo nephrectomy. Fifteen of the 16 patients with clear cell renal cancer showed accumulation of the 124 I-labeled anti-carbonic anhydrase IX antibody in their primary tumor. None of the 9 patients with other renal masses showed any such accumulation (6) . This study indicated that immuno-PET might be helpful in clinical decision making and might aid in the surgical management of small renal masses scheduled for partial nephrectomy. These promising results formed the basis for a recently completed multicenter phase III registration trial in 226 patients (7) . Although publication of the full data is pending and approval has not yet been granted by the Food and Drug Administration, first communications of the results seem favorable (8) .
Still, immuno-PET has important advantages over conventional radioimmunoscintigraphy. Immuno-PET provides not only higher-resolution images but also the concentration of the radiolabeled antibody in tissues of interest could be derived accurately from the images. In their report, Carrasquillo et al. elegantly validated this statement by demonstrating that the pharmacokinetics and tissue concentrations derived from the PET images were essentially the same as derived from the ex vivo measurements of blood and tissue samples in a g-counter (3). This advantage could be exploited especially in myeloablative radioimmunotherapy to determine the maximum dose of activity that can safely be administered based on estimates of radiation doses to doselimiting organs. It has been shown that radiation doses of radioimmunotherapy with 90 Y-ibritumomab tiuxetan (Zevalin; Spectrum Pharmaceuticals) can be predicted by immuno-PET with 89 Zr-ibritumomab tiuxetan (9) . The same group showed that this dose prediction also applies to radioimmunotherapy with 177 Lu-and 90 Y-labeled antibodies. However, for radioimmunotherapy with internalizing antibodies, the radiation dose to the bone marrow will be overestimated if based on 89 Zr-dosimetry (10) .
Immuno-PET could also be applied to quantitatively estimate expression of accessible antigens in the target tissue. Potentially, this application could lead to patient stratification of antibodybased therapies such as trastuzumab therapy in breast cancer patients. In current clinical practice, patients with metastasized breast cancer are eligible to be treated with trastuzumab if overexpression of the HER2 receptor in a tumor sample can be shown immunohistochemically or by in situ hybridization. It could be argued that this patient stratification can be done more accurately on the basis of immuno-PET, because 89 Zr-trastuzumab imaging can show actual targeting of cancer lesions in vivo (11) .
Another important application of immuno-PET could be its use in the development of antibody-based drugs. PET of the 124 I-or 89 Zr-labeled antibody drug in patients could provide useful quantitative information about pharmacokinetics, accumulation in targeted and nontargeted tissues, and saturation of the target antigen. Accurate dosing of a newly developed antibody could be based on immuno-PET studies, possibly speeding the development of antibody-based drugs. When analyzing the results of these studies, one should realize that immuno-PET shows the in vivo distribution of the radionuclide and that, when the radiolabeled antibody is metabolized in vivo, this distribution does not necessarily represent the immunoreactive antibody. This consideration is particularly relevant for internalizing antibodies: when the target cell internalizes the radiolabeled antibody, the antibody is catabolized in the lysosomes and the radiolabeled metabolite will either be released from the cell (e.g., 124 I-labeled tyrosine) or residualize in the cell (e.g., 89 Zr-desferal-lysine).
It appears that immuno-PET is just the beginning of a series of new technologic developments. New antibody formats, such as single-chain antibodies, diabodies, Nanobodies (Ablynx), and minibodies have now been labeled with positron emitters, allowing rapid imaging with high contrast (12) . Affibody molecules, 7-kDa scaffolds derived from protein A with high affinity for HER2, epidermal growth factor receptor, and other tumor targets have now been labeled with 68 Ga and 18 F (13) and can be used to determine receptor expression in cancer patients (14) . Because of the rapid pharmacokinetics for immuno-PET with these constructs, shorter-lived positron emitters are used: 68 Ga (T 1/2 5 1 h), 18 F (T 1/2 5 2 h), 64 Cu (T 1/2 5 13 h), and 76 Br (T 1/2 5 16 h).
Tumor-to-background ratios in antibody imaging can be improved by using pretargeting approaches. The tumor is pretargeted with a bispecific antibody with affinity for the tumorassociated antigen and for a hapten. After the tumor has been pretargeted with the bispecific antibody, the radiolabeled peptide conjugated with the hapten is injected. In a few pretargeting studies in mouse models, peptides labeled with positron-emitting radionuclides ( 124 I, 68 Ga, or 18 F) were used (15) (16) (17) . These studies showed that with pretargeted immuno-PET, highcontrast images can be obtained that could be more sensitive and specific than 18 F-FDG PET images. Pretargeted immuno-PET will soon be tested in cancer patients.
In conclusion, immuno-PET is a new technology that caused a revival of antibody imaging in cancer patients and can be applied for tailored patient management, dose calculation in radioimmunotherapy, and development of antibody-based drugs.
